GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bristol-Myers Squibb Co (OTCPK:BMYMP.PFD) » Definitions » EV-to-EBIT

BMYMP.PFD (Bristol-Myers Squibb Co) EV-to-EBIT : 0.08 (As of May. 17, 2025)


View and export this data going back to . Start your Free Trial

What is Bristol-Myers Squibb Co EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Bristol-Myers Squibb Co's Enterprise Value is $647.00 Mil. Bristol-Myers Squibb Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was $8,124.00 Mil. Therefore, Bristol-Myers Squibb Co's EV-to-EBIT for today is 0.08.

The historical rank and industry rank for Bristol-Myers Squibb Co's EV-to-EBIT or its related term are showing as below:

BMYMP.PFD' s EV-to-EBIT Range Over the Past 10 Years
Min: -71.11   Med: 17.25   Max: 52.41
Current: 16.58

During the past 13 years, the highest EV-to-EBIT of Bristol-Myers Squibb Co was 52.41. The lowest was -71.11. And the median was 17.25.

BMYMP.PFD's EV-to-EBIT is ranked worse than
50.07% of 685 companies
in the Drug Manufacturers industry
Industry Median: 16.34 vs BMYMP.PFD: 16.58

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Bristol-Myers Squibb Co's Enterprise Value for the quarter that ended in Mar. 2025 was $0.00 Mil. Bristol-Myers Squibb Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was $8,124.00 Mil. Bristol-Myers Squibb Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 was %.


Bristol-Myers Squibb Co EV-to-EBIT Historical Data

The historical data trend for Bristol-Myers Squibb Co's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bristol-Myers Squibb Co EV-to-EBIT Chart

Bristol-Myers Squibb Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -31.75 17.25 20.21 13.84 -24.12

Bristol-Myers Squibb Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -34.72 -26.98 -29.01 -24.12 20.14

Competitive Comparison of Bristol-Myers Squibb Co's EV-to-EBIT

For the Drug Manufacturers - General subindustry, Bristol-Myers Squibb Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bristol-Myers Squibb Co's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bristol-Myers Squibb Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Bristol-Myers Squibb Co's EV-to-EBIT falls into.


;
;

Bristol-Myers Squibb Co EV-to-EBIT Calculation

Bristol-Myers Squibb Co's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=647.000/8124
=0.08

Bristol-Myers Squibb Co's current Enterprise Value is $647.00 Mil.
Bristol-Myers Squibb Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $8,124.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bristol-Myers Squibb Co  (OTCPK:BMYMP.PFD) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Bristol-Myers Squibb Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2025 ) =EBIT / Enterprise Value (Q: Mar. 2025 )
=8124/0
= %

Bristol-Myers Squibb Co's Enterprise Value for the quarter that ended in Mar. 2025 was $0.00 Mil.
Bristol-Myers Squibb Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $8,124.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bristol-Myers Squibb Co EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Bristol-Myers Squibb Co's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Bristol-Myers Squibb Co Business Description

Address
Route 206 and Province Line Road, Princeton, New Jersey, NJ, USA, 08543
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.